% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Reijs:138197,
author = {Reijs, Babette L R and Teunissen, Charlotte E and
Goncharenko, Nikolai and Betsou, Fay and Blennow, Kaj and
Baldeiras, Inês and Brosseron, Frederic and Cavedo, Enrica
and Fladby, Tormod and Froelich, Lutz and Gabryelewicz,
Tomasz and Gurvit, Hakan and Kapaki, Elisabeth and Koson,
Peter and Kulic, Luka and Lehmann, Sylvain and Lewczuk,
Piotr and Lleó, Alberto and Maetzler, Walter and de
Mendonça, Alexandre and Miller, Anne-Marie and Molinuevo,
José L and Mollenhauer, Brit and Parnetti, Lucilla and Rot,
Uros and Schneider, Anja and Simonsen, Anja Hviid and
Tagliavini, Fabrizio and Tsolaki, Magda and Verbeek, Marcel
M and Verhey, Frans R J and Zboch, Marzena and Winblad,
Bengt and Scheltens, Philip and Zetterberg, Henrik and
Visser, Pieter Jelle},
title = {{T}he {C}entral {B}iobank and {V}irtual {B}iobank of
{BIOMARKAPD}: {A} {R}esource for {S}tudies on
{N}eurodegenerative {D}iseases.},
journal = {Frontiers in neurology},
volume = {6},
issn = {1664-2295},
address = {Lausanne},
publisher = {Frontiers Research Foundation},
reportid = {DZNE-2020-04519},
pages = {216},
year = {2015},
abstract = {Biobanks are important resources for biomarker discovery
and assay development. Biomarkers for Alzheimer's and
Parkinson's disease (BIOMARKAPD) is a European multicenter
study, funded by the EU Joint Programme-Neurodegenerative
Disease Research, which aims to improve the clinical use of
body fluid markers for the diagnosis and prognosis of
Alzheimer's disease (AD) and Parkinson's disease (PD). The
objective was to standardize the assessment of existing
assays and to validate novel fluid biomarkers for AD and PD.
To support the validation of novel biomarkers and assays, a
central and a virtual biobank for body fluids and associated
data from subjects with neurodegenerative diseases have been
established. In the central biobank, cerebrospinal fluid
(CSF) and blood samples were collected according to the
BIOMARKAPD standardized pre-analytical procedures and stored
at Integrated BioBank of Luxembourg. The virtual biobank
provides an overview of available CSF, plasma, serum, and
DNA samples at each site. Currently, at the central biobank
of BIOMARKAPD samples are available from over 400 subjects
with normal cognition, mild cognitive impairment (MCI), AD,
frontotemporal dementia (FTD), vascular dementia, multiple
system atrophy, progressive supranuclear palsy, PD, PD with
dementia, and dementia with Lewy bodies. The virtual biobank
contains information on over 8,600 subjects with varying
diagnoses from 21 local biobanks. A website has been
launched to enable sample requests from the central biobank
and virtual biobank.},
cin = {AG Heneka / AG Maetzler / AG Schneider Göttingen},
ddc = {610},
cid = {I:(DE-2719)1011303 / I:(DE-2719)5000024 /
I:(DE-2719)1440011},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26528237},
pmc = {pmc:PMC4606063},
doi = {10.3389/fneur.2015.00216},
url = {https://pub.dzne.de/record/138197},
}